1. Home
  2. GDV vs IBRX Comparison

GDV vs IBRX Comparison

Compare GDV & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Dividend & Income Trust of Beneficial Interest

GDV

Gabelli Dividend & Income Trust of Beneficial Interest

HOLD

Current Price

$28.63

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$6.23

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GDV
IBRX
Founded
2003
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GDV
IBRX
Price
$28.63
$6.23
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$11.80
AVG Volume (30 Days)
186.0K
46.1M
Earning Date
01-01-0001
03-02-2026
Dividend Yield
5.81%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$82,555,000.00
Revenue This Year
N/A
$680.06
Revenue Next Year
N/A
$90.18
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1025.95
52 Week Low
$18.04
$1.83
52 Week High
$23.00
$8.28

Technical Indicators

Market Signals
Indicator
GDV
IBRX
Relative Strength Index (RSI) 64.54 75.41
Support Level $28.43 $5.71
Resistance Level $28.50 $8.28
Average True Range (ATR) 0.22 0.67
MACD -0.00 0.42
Stochastic Oscillator 88.31 67.10

Price Performance

Historical Comparison
GDV
IBRX

About GDV Gabelli Dividend & Income Trust of Beneficial Interest

Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: